HYDERABAD, India & PRINCETON, N.J., January 14, 2026--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr.
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S. Dr.
Medicare selected Botox and Trulicity among 15 high-cost drugs for price negotiations under new federal authority, with lower prices expected in 2028. Rep. Rich McCormick, R-Ga., discusses President ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results